Dear Non-registered Holder(s) (Note) , BESUNYEN HOLDINGS COMPANY LIMITED (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號: 926) Besunyen Holdings Company Limited (the "Company") - Extraordinary General Meeting ("EGM") of the Company to be held on Monday, 25 August 2025 The EGM of the Company will be held virtually using online platform at http://meetings.computershare.com/Besunyen_EGM202508 (the "Online Platform") at 10:30 a.m. on Monday, 25 August 2025. Sharehol ...

You will be able to view the live video broadcast of the EGM, cast your votes on the resolutions in real time and submit questions to the Company. From 10:00 a.m. on Monday, 25 August 2025, you can log in to the Online Platform for the EGM by visiting the meeting website and entering the following details: BESUNYEN HOLDINGS COMPANY LIMITED (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號: 926) Dear Shareholder(s), 8 August 2025 Besunyen Holdings Company Limited ( ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 BESUNYEN HOLDINGS COMPANY LIMITED 碧生源控股有限公司 （於開曼群島註冊成立的有限公司） 茲通告碧生源控股有限公司（「本公司」）謹訂於二零二五年八月二十五日（星期一）上 午十時三十分以電子方式舉行股東特別大會（「股東特別大會」），以進行下列事宜： 普通決議案 「動議謹此批准自本公司的股份溢價賬中宣派及派發中期股息每股普通股0.15港元 （「中期股息」），並謹此授權本公司任何一名董事（或如須加蓋公司印鑑，則授權本 公司任何兩名董事）按其全權酌情認為就上述各項而言屬必需、適宜、合適及權宜 者採取行動、進行事宜並簽立文件及契據。」 承董事會命 碧生源控股有限公司 （股份代號：926） 股東特別大會通告 – 1 – 附註： 1. 股 東 特 別 大 會 將 以 電 子 方 式 舉 行 。 登 記 股 東 將 可 到 訪 網 站 http://meetings.computersh ...

將於二零二五年八月二十五日（星期一）舉行之股東特別大會 （或其任何續會）之代表委任表格 碧生源控股有限公司 BESUNYEN HOLDINGS COMPANY LIMITED （於開曼群島註冊成立的有限公司） （股份代號：926） 日期 簽署 股本中每股面值0.0003333332美元股份（「股份」） 股 之登記持有人，茲委任本公司股東特別大會（「大會」）主席 （附註3） 或 地址為 （電郵地址） 擔任本人╱吾等受委代表，為及代表本人╱吾等出席本公司謹訂於二零二五年八月二十五日（星期一）上午十時 三十分以電子形式舉行之大會（或其任何續會），藉以考慮並酌情通過召開大會通告（「通告」）所載之決議案，並 在大會（或其任何續會）代表本人╱吾等按照以下指示以本人╱吾等名義就有關決議案投票 （附註4） ： | 誠如通告決議案所載，批准自本公司股份溢價賬中宣派及派發中期股 | | | | | | --- | --- | --- | --- | --- | | 普通決議案 息每股普通股0.15港元，以及其附帶的所有事宜。 | 贊成 | （附註4） | 反對 | （附註4） | 本人╱吾等 （附註1） 地址為 為碧生源控股有限 ...

BESUNYEN HOLDINGS COMPANY LIMITED 碧生源控股有限公司 閣下如已將名下的碧生源控股有限公司股份全部出售或轉讓，應立即將本通函連同隨附的 代表委任表格送交買主或承讓人，或經手出售或轉讓的銀行經理、持牌證券交易商或其他代 理商，以便轉交買主或承讓人。 閣下對本通函的任何內容或應採取的行動如有任何疑問，應諮詢 閣下的持牌證券交易商或 其他註冊證券機構、銀行經理、律師、專業會計師或其他專業顧問。 （於開曼群島註冊成立的有限公司） （股份代號：926） 此 乃 要 件 請 即 處 理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 建議宣派及派發中期股息 及 股東特別大會通告 碧生源控股有限公司謹訂於二零二五年八月二十五日（星期一）上午十時三十分以電子方式 舉行股東特別大會，召開股東特別大會的通告載於本通函第7至9頁。 無論 閣下能否出席股東特別大會，務請按隨附的代表委任表格印列的指示填妥表格，盡快 但無論如何於股東特別大會或其任 ...

Core Viewpoint - Biyuan's performance in the first half of 2025 shows steady progress, with revenue reaching 258.9 million RMB, a year-on-year increase of 1.8% [1]. Financial Performance - Total comprehensive income reached 12.4 million RMB, up 45.9% from 8.5 million RMB in the same period last year [1]. - The company's profitability is recovering, with a net profit attributable to shareholders of 14.8 million RMB in 2024, compared to a loss of 299 million RMB in 2023 [3]. - Gross margin improved significantly from 46.91% in 2023 to 67.28% in 2024, indicating effective product structure optimization and cost control measures [3]. Product Performance - The traditional "Four Teas" business generated revenue of 129.1 million RMB, a decline of 4.7% year-on-year, reflecting increased competition and changing consumer demand in the health tea market [4]. - The weight loss drug segment saw revenue of 94.4 million RMB, a growth of 15.0%, primarily due to the ongoing promotion of the Orlistat product [4]. Business Transformation - Biyuan is implementing a profit-centered business improvement strategy, transitioning its offline OTC business through joint ventures, which has led to improved operational quality [3]. - The company has made significant progress in channel development, covering nearly 290,000 OTC pharmacies and medical third terminals across 31 provinces and cities in China [3]. Future Development Strategy - The company plans to leverage the "Weight Management Year" initiative promoted by the National Health Commission, focusing on the core health tea business while deepening reforms and optimizing mechanisms [6]. - Biyuan aims to enhance its brand building and youth-oriented marketing strategies through diversified media channels, targeting younger consumer demographics [4][6]. - Financial health indicators show improvement, with the current ratio rising from 1.58 in 2021 to 2.96 in 2024, and the debt-to-asset ratio decreasing from 35.73% to 15.22% [6].

Core Insights - The company's revenue for the first half of 2025 reached 259 million RMB, representing a year-on-year growth of 1.82% [1] - The net profit of the company was 12.402 million RMB, showing a significant year-on-year increase of 58.74% [1] - Basic earnings per share were reported at 10.14 cents [1] Revenue Growth - The primary driver for revenue growth was the strong performance of online e-commerce channels [1]

Core Viewpoint - The company reported a revenue of RMB 259 million for the six months ending June 30, 2025, reflecting a year-on-year increase of 1.82% and a net profit of RMB 12.402 million, which is a significant year-on-year increase of 58.74% [1] Financial Performance - Revenue for the period was RMB 259 million, up 1.82% year-on-year [1] - Net profit reached RMB 12.402 million, marking a 58.74% increase compared to the previous year [1] - Basic earnings per share were reported at 10.14 cents [1] - The company proposed an interim dividend of HKD 0.15 per share [1] Revenue Drivers - The increase in revenue was primarily attributed to strong performance in online e-commerce channels, which partially offset the temporary pressure faced by traditional offline channels [1]

智通财经APP讯，碧生源(00926)发布截至2025年6月30日止6个月中期业绩，该公司取得收入人民币2.59 亿元(单位下同)，同比增加1.82%;净利润1240.2万元，同比增加58.74%;每股基本盈利10.14分。拟派发中 期股息每股0.15港元。 公告称，收入增加主要是由于线上电商渠道的强劲表现，部分抵消传统线下渠道的阶段性承压产生。 ...

Core Points - The company reported a revenue of RMB 259 million for the first half of 2025, representing a year-on-year increase of 1.8% [1] - The total comprehensive income attributable to owners of the company for the first half of 2025 was RMB 12.4 million, compared to RMB 8.5 million in the same period of 2024 [1] - Basic and diluted earnings per share for the first half of 2025 were RMB 0.1014, up from RMB 0.0639 in the first half of 2024 [1] - The board has proposed an interim dividend of HKD 0.15 per share for the six months ending June 30, 2025 [1] Business Strategy - The company continues to adhere to a work tone of seeking progress while maintaining stability, focusing on business improvements centered around profitability [1] - The quality of distribution, agency, and service work for the company's products has significantly improved through the efforts of the company and its joint ventures [1] - The company has achieved a smooth transition and steady development of its offline OTC business and has initiated further reform objectives [1] - The online operation model has become more mature and efficient, contributing to the gradual enhancement of online operational efficiency and effectiveness [1] - Overall operational quality of the company has seen significant improvement [1]